Lakefront Biotherapeutics stock analysis
Want to see LKFT full AI Analyst Report?
Lakefront Biotherapeutics (LKFT) Stock Price & Analysis
LKFT Stock Chart & Stats
- Day’s Range
- $33.22 - $34.14
- 52-Week Range
- $25.68 - $36.24
- Previous Close
- $33.93
- Volume
- N/A
- Average Volume (3M)
- 280.32K
- Market Cap
- $2.19B
- Enterprise Value
- -$529.52M
- Total Cash (Recent Filing)
- $2.22B
- Total Debt (Recent Filing)
- $3.15M
- Price to Earnings (P/E)
- 4.1
- Beta
- 0.57
- Next Earnings
- Feb 24, 2027 (Est.)
- EPS Estimate
- -0.7
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet
Minimal debt relative to equity and substantial equity relative to assets give Lakefront financial flexibility. That cushion can support continued investment and help absorb operating volatility without the immediate pressure of heavy interest obligations or refinancing needs.
TTM Profitability
TTM results show very high gross profit and solid operating and net margins, with net income improving versus earlier annual periods. If sustained, this profitability provides internal earnings capacity to fund development and strengthen the business model.
Revenue Growth
The reported 240.8% revenue growth indicates that Lakefront has demonstrated the ability to expand its topline materially. Such scaling can improve operating leverage and broaden the base supporting future earnings, although consistency remains important.
Bears Say
Persistent Cash Burn
Persistent negative operating and free cash flow means reported profits are not translating into cash generation. Continued cash burn can increase reliance on balance-sheet resources, constrain investment choices, and raise execution risk if operating performance weakens.
Inconsistent Profitability
Earlier losses and inconsistent returns make the current profitability profile less predictable than the latest results alone suggest. This history reduces confidence that margins and earnings can remain durable through changing business conditions over the next several quarters.
Recent Revenue Decline
The TTM revenue decline following a strong 2025 step-up indicates that growth has not yet become consistently repeatable. Uneven topline performance can limit operating leverage, complicate planning, and make future earnings less dependable despite current margins.
Lakefront Biotherapeutics News
LKFT FAQ
What was Lakefront Biotherapeutics’s price range in the past 12 months?
What is Lakefront Biotherapeutics’s market cap?
When is Lakefront Biotherapeutics’s upcoming earnings report date?
How were Lakefront Biotherapeutics’s earnings last quarter?
Is Lakefront Biotherapeutics overvalued?
Does Lakefront Biotherapeutics pay dividends?
What is Lakefront Biotherapeutics’s EPS estimate?
How many shares outstanding does Lakefront Biotherapeutics have?
What happened to Lakefront Biotherapeutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Lakefront Biotherapeutics?
What is the TipRanks Smart Score and how is it calculated?
Lakefront Biotherapeutics Stock Smart Score
Company Description
Lakefront Biotherapeutics
Lakefront Biotherapeutics NV, formerly Galapagos NV, is a biotechnology company that focuses on transforming patient outcomes through scientific innovation. It is dedicated to building a pipeline of medicines for patients with serious diseases in therapeutic areas of unmet need, prioritizing oncology and immunology & inflammation programs. The company's clinical-stage portfolio is anchored by potential first-in-class treatments for autoimmune diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Henry Gosebruch
- Employees
- 452
- Website
- lakefrontbio.com
- Address
- SchaliEnhoevedreef 20 T, Mechelen, 2800, BE
Lakefront Biotherapeutics (LKFT) Earnings & Revenues
LKFT Earnings Call
Earnings Call SentimentPositive
The call highlights a major strategic transformation with a high‑profile Ouro/Gilead transaction that brings a promising clinical asset (gamgertamig) and unlocks substantial financial flexibility. Operationally, the company reported meaningful quarterly improvement in operating loss and a net profit driven by financial gains, maintained a strong cash position, and emphasized cost discipline and capital‑efficient development plans. Offsetting these positives are a very large near‑term cash deployment (upfront and wind‑down costs), a steep YoY revenue decline driven by prior‑year accounting recognition, continued operating losses, and clinical and competitive risks inherent to the BCMA/CD3 space. On balance, the strategic upside and improved reported results outweigh the near‑term financial outflows and risks.
View all LKFT earnings summariesLKFT Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 5 | 2 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 12 | 0 | 0 |












